SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2018
CRISPR THERAPEUTICS AG
(Exact Name of Company as Specified in Charter)
(State or Other Jurisdiction
+41 61 228 7800
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|Item 8.01|| |
On November 8, 2018, CRISPR Therapeutics AG (the Company) issued 214,512 common shares (the Shares) to ViaCyte, Inc. (ViaCyte), pursuant to the terms of that certain Research and Collaboration Agreement, dated September 17, 2018, by and between the Company and ViaCyte.
The issuance of the Shares was made pursuant to the Companys effective shelf registration statement on Form S-3 (File No. 333-221491), including the prospectus dated December 4, 2017, as supplemented by a prospectus supplement dated September 24, 2018.
The legal opinion of VISCHER AG relating to the legality of the issuance of the Shares is attached as Exhibit 5.1 to this Current Report on Form 8-K.
|Item 9.01.|| |
Financial Statements and Exhibits.
|5.1||Opinion of VISCHER AG|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CRISPR THERAPEUTICS AG|
|Date: November 8, 2018||By:||/s/ Samarth Kulkarni|
|Chief Executive Officer|
CRISPR Therapeutics AG
Basel, November 8, 2018
CRISPR Therapeutics AG Registration Statement on Form S-3
Phone +41 58 211 33 00
Fax +41 58 211 33 10
Phone +41 58 211 34 00
Fax +41 58 211 34 10
Civil Law Notaries in
Dear Sir or Madam,
We have acted as Swiss counsel to CRISPR Therapeutics AG (the Company), a company incorporated under the laws of the Switzerland, in connection with the Companys registration statement on Form S-3 as filed with the U.S. Securities and Exchange Commission (the Commission), as amended or supplemented (the Registration Statement), with respect to the registration under the U.S. Securities Act of 1933, as amended (the Securities Act), and the related prospectus covering the Shelf Securities dated November 8, 2018 in the form first used to confirm sales of the offered securities (the Prospectus) supplemented by the prospectus supplement (the Supplement) specifically relating to the offer and sale of 214,512 ordinary shares of the Company (the Shares). The Shares have been created through a capital increase under Swiss Law.
I. BASIS OF OPINION
This opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof and as currently applied by Swiss courts. In the absence of statutory or established case law, we base our opinion on our independent professional judgement.
This opinion is also confined to the matters stated herein and is not to be read as extending, by implication or otherwise, to any other matter.
For the purpose of giving this opinion, We have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement, (ii) the Prospectus, (iii) the Supplement, (iv) a copy of the coordinated articles of association of the Company as at September 21, 2018, and (v) such corporate documents and records of the Company and such other instruments, certificates and documents as we have deemed necessary or appropriate as a basis for the opinions hereinafter expressed. In such examinations, we have assumed the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies or drafts of documents to be executed, the genuineness of all signatures and the legal competence or capacity of persons or entities to complete the execution of documents. As to various questions of fact that are material to the opinions hereinafter expressed, we have relied upon statements or certificates of public officials, directors and officers of the Company and others.
The documents referred to above in paragraphs are referred to together as the Documents. No documents have been reviewed by ourselves in connection with this opinion other than those listed above. Accordingly, our opinion is limited to the above Documents and their legal implications under Swiss law.
All terms used in this opinion in uppercase form shall have the meaning ascribed to them in the Registration Statement, unless otherwise defined herein.
In rendering the opinion below, we have assumed:
a) the conformity to the Documents of all documents produced to us as copies, fax copies or via e-mail, and that the original was executed in the manner appearing on the copy of the draft;
b) the genuineness and authenticity of the signatures on all copies of the original Documents thereof which we have examined; and
c) to the extent relevant for purposes of this opinion, all factual information contained in, or material statements given in connection with, the Documents are true, complete and accurate.
Based upon the foregoing and subject to the qualifications set out below, we are of the opinion that the Shares will be validly issued, fully paid-in (up to their nominal amount) and non-assessable (which term means when used herein that no further contributions have to be made by the holders of the Shares).
This opinion is subject to the following qualifications:
a) This opinion is limited to matters of Swiss law as in force on the date hereof and as applied and construed by the courts of Switzerland.
b) The opinion set forth herein is limited to the matters specifically addressed herein, and no other opinion or opinions are expressed or may be implied or inferred. In particular we express no opinion as to any commercial, calculating, auditing or other non-legal matters. Further, we express no opinion as to tax law.
* * *
We have rendered this opinion as of the date hereof and we assume no obligation to advise you of changes that may thereafter be brought to our attention.
In this opinion, Swiss legal concepts are expressed in English terms and not in their original terms. The concepts concerned may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions. All liability and other matters relating to this opinion shall be governed exclusively by Swiss law.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Legal Matters contained in the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.
Very truly yours,
/s/ Matthias Staehelin
Dr. Matthias Staehelin